Tindamax® (tinidazole), a second-generation nitroimidazole, is an antiprotozoal drug which is used to treat certain types of parasitic infections, including the sexually transmitted disease trichomoniasis, also known as "trich." Tindamax® is also indicated to treat the intestinal parasitic infections giardiasis and amebiasis, as well as amebic liver infections.
When approved by the FDA in May 2004, Tindamax® marked the first advancement in the treatment of trichomoniasis in over 40 years. Additionally, the recently approved supplemental indication for the treatment of bacterial vaginosis (BV) makes Tindamax® the first oral therapy approved for this condition in a decade.
Compared to the current standard of care:
- Tindamax® has a long serum half-life (12-14 hours v. 6-7 hours).
- Tindamax® has an excellent safety profile and a low incidence of gastrointestinal side effects.
- Additionally, increased lipid solubility of Tindamax® results in more efficient tissue absorption.
Bacterial vaginosis (BV)
- Clinical trial data show once-daily Tindamax® to be significantly superior to placebo in treating BV, and as well-tolerated and safe as compared to placebo.
- Unlike intravaginal treatments such as creams or gels, Tindamax® treats the entire reproductive tract systematically, including the upper tract, where BV has been shown to migrate.
- Administered as one gram (two tablets) once daily for five days or two grams (four tablets) once daily for two days, Tindamax® provides a shorter and more convenient oral treatment for bacterial vaginosis than the current standard of care.
Trichomoniasis
- Tindamax® is recommended as one of the drugs of choice for the treatment of trichomoniasis by the Centers for Disease Control and Prevention (CDC).1
- In over 30 clinical studies of trichomoniasis, Tindamax® has demonstrated cure rates of 92 to 100 percent in both women and men.
- Tindamax® effectively treats trichomoniasis in one dose, while sparing protective vaginal lactobacilli.
Giardiasis (giardia)
- Tindamax® is recommended as one of the drugs of choice for the treatment of giardiasis by the Centers for Disease Control and Prevention (CDC).2
- Tindamax® is the only single-dose oral therapy approved to treat giardiasis.
- Single-dose Tindamax® for giardiasis has demonstrated cure rates of 80 to 100 percent
- The Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines, 2006. Available at http://www.cdc.gov/std/treatment/2006/toc.htm. Accessed January 30, 2007.
- The Centers for Disease Control and Prevention: Health Guide for International Travelers, 2005-2006. Available at http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=dis&obj=giardiasis.htm. Accessed January 31, 2007.
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
